Sodium cromoglicate inhalant - AZTherapies

Drug Profile

Sodium cromoglicate inhalant - AZTherapies

Alternative Names: ALZT OP1a; Cromolyn - AZTherapies; Sodium cromoglicate - AZTherapies

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AZTherapies
  • Class Antiallergics; Antiasthmatics; Antihyperglycaemics; Antitussives; Benzopyrans; Chromones; Nootropics; Skin disorder therapies; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cognition disorders

Most Recent Events

  • 04 Aug 2017 Chemical structure information added
  • 04 Jul 2017 AZTherapies has patent protection for cromolyn derivatives and its preparation for imaging and therapeutic applications
  • 26 Jun 2017 Clinical trials in Cognition disorders (Adjuvant therapy) in USA prior to June 2017 (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top